Physician profile
Foluso Ogunleye
NPI 1972766772
$11,034.07
in general payments reported to CMS, 2019-2025
68 companies · $2,927 in 2025
The $2,927 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,426 · 2020: $426 · 2021: $1,085 · 2022: $2,907 · 2023: $384 · 2024: $1,879 · 2025: $2,927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,561 · Travel and Lodging: $1,182 · Long Term Medical Supply Or Device Loan: $299 · Education: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,560.71 |
| Travel and Lodging | $1,182.05 |
| Long Term Medical Supply Or Device Loan | $299.10 |
| Education | $147.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Uk Limited | $1,612.05 | 2024 | |
| Novartis Pharmaceuticals Corporation | $1,154.03 | 2019-2025 | |
| Daiichi Sankyo INC. | $686.48 | 2019-2025 | Enhertu |
| Pfizer INC. | $552.94 | 2019-2025 | |
| Janssen Biotech, INC. | $538.54 | 2019-2025 | Erleada, Rybrevant, Darzalex |
| Amgen INC. | $525.22 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $429.62 | 2019-2025 | Calquence, Imfinzi |
| Celgene Corporation | $421.38 | 2019-2025 | Breyanzi, Reblozyl, Opdivo |
| Genzyme Corporation | $317.80 | 2019-2024 | |
| Seagen INC. | $293.28 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $284.99 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $271.55 | 2022-2025 | Rezlidhia, Tavalisse, Tavalisse |
| E.R. Squibb & Sons, L.L.C. | $255.90 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $254.42 | 2019-2025 | |
| Incyte Corporation | $218.42 | 2019-2025 | Jakafi, Monjuvi |
Show all 67 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Foluso Ogunleye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.